The Endpoints 100: What impact has Trump 2.0 had on biotech? And what comes next?

Our E100 survey for H1, 2025 is coming together in extraordinary times. A major reorganization of the FDA is underway and Trump’s tariff war is raising alarms about imports and the economy.

What have biotech execs been seeing? And what are they losing sleep over these days? We’ll cover the results of our survey in a wide-ranging panel conversation with a group of industry leaders.

This is one conversation you won’t want to miss.